Sortino, Rosalba, Gonzalez-Diez, Aleix, Milla-Navarro, Santiago, Martinez-Tambella, Joaquin, Paleo-Garcia, Victor, Calatayud, Eric, de Saralegui, Paula, Opar, Ekin, Claparols, Alvar, Quintanilla, Josecarlo A, Martinez-Soler, Xavier, Riefolo, Fabio, Matera, Carlo, Hernando, Jordi, Gomila, Alexandre M J, Perez-Batlle, Gerard, Pereira, Carles, Camarero, Nuria, Serra, Carme, Gomez-Santacana, Xavier, Llebaria, Amadeu, Rovira, Xavier, de la Villa, Pedro, Gorostiza, Pau, (2026). Restoration of SaccadicEye Movements and VisuallyGuided Behavior in Ambient White Light with Photoswitchable SmallMoleculesJOURNAL OF THE AMERICAN CHEMICAL SOCIETY 148, 31701-31715
Blinding diseases due to the degeneration of photoreceptors (PhRs), such as geographic atrophy (GA) secondary to dry age-related macular degeneration and retinitis pigmentosa (RP), leave the rest of the retinal circuitry largely intact, albeit unable to respond to light. Gene therapy has been able to revert PhR degeneration, but it can be applied only to a rare mutation affecting a small subset of RP patients. Alternatively, implanted electronic retinal prostheses aim at a larger population by electrically stimulating surviving neurons. However, the treatment is invasive and costly and provides limited resolution. Photopharmacology can develop photoswitchable small molecules to restore vision impairment by conferring light sensitivity to ion channels that are widely expressed in the remaining inner retinal neurons, and a first-in-human clinical trial is ongoing. Here, we have developed novel photoswitchable small-molecule ligands of metabotropic glutamate 6 (mGlu6) receptors, which are located exclusively at the dendrites of ON bipolar cells (postsynaptic to PhRs) and can leverage a privileged position to mimic physiological signals in the remnant retinal circuit. These photoswitchable ligands (prosthe6) thus act as "molecular prostheses" that can restore the light input to the retina via upstream-targeted control of the circuit after PhR degeneration. Prosthe6 compounds are allosteric, drug-like, water-soluble, and display outstanding in vitro properties including full efficacy, nanomolar potency, fast deactivation in ambient white light, and fast reactivation in the dark. In vivo experiments show that they readily recover the saccadic eye movements of blinded zebrafish larvae and restore the innate light-avoidance behavior in the mouse models of blindness (GA and RP). These effects are mediated by mGlu6 receptors in vivo. In addition, at least two compounds (prosthe6-12 and -15) can restore sight by topical administration and display promising safety properties to become potential drug candidates for sight restoration in patients with degenerative blinding diseases.
Despite significant efforts in developing novel biomaterials to regenerate tissue, only a few of them have successfully reached clinical use. It has become clear that the next generation of biomaterials must be multifunctional. Smart biomaterials can respond to environmental or external stimuli, interact in a spatial-temporal manner, and trigger specific tissue/organism responses. In this study, the fabrication of novel 3D-printed and bioresorbable scaffolds, with embedded crystals that can convert near-infrared (NIR) light into visible light, is presented. It is demonstrated that these biophotonic scaffolds are not only bioactive and bioresorbable, but can also be promising as a platform for the controlled release or activation of photoactivated drugs locally and on demand, under illumination. The scaffolds are analyzed based on their up-conversion spectroscopic properties and their chemical stability in simulated body fluid. Furthermore, it is demonstrated that the up-conversion properties of the scaffolds are sufficient to release the signaling molecule nitric oxide (NO) and to photoisomerize the muscarinic ligand Phthalimide-Azo-Iperoxo (PAI), in a controlled manner, upon NIR light stimulus. Finally, to assess their biocompatibility for potential implantation, a preliminary study is conducted with human adipose stem cells cultured in contact with scaffolds. Live/dead assays, morphological analysis, CyQUANT analysis, and ion release measurements confirm that, despite some release of the upconverter crystals, the biophotonic materia and its dissolution by-products, are biocompatible. These findings highlight the potential of these bioresorbable biophotonic scaffolds for localized drug release in response to NIR light stimuli.
The fabrication of porous biophotonic scaffold using a robocasting is reported here. Such material could be used for in-situ activation of photoswitchable drugs, which is essential for improving therapeutic efficacy while minimizing side effects. The scaffold is made of a phosphate glass mixed with CaWO4:Yb3 +,Tm3 + crystals and SrAl2O4:Eu2+,Dy3 + phosphors. Upon 980 nm irradiation, the scaffold emits blue light and green afterglow, enabling in-situ activation post-implantation as NIR light penetrates tissue. The challenges related to the sintering process and its effect on the spectroscopic properties of the scaffold are discussed. The as-3D printed scaffold successfully enables one to activate the muscarinic photoswitchable drug Phthal Azobenzene Iperoxo (PAI) upon NIR excitation, confirming the potential for in-situ phototriggered delivery of drug action using tissue-permeable light stimulus.
The field of G protein-coupled receptor (GPCR) research has greatly benefited from the spatiotemporal resolution provided by light controllable, i.e., photoswitchable ligands. Most of the developed tools have targeted the Rhodopsin-like family (Class A), the largest family of GPCRs. However, to date, all such Class A photoswitchable ligands were designed to act at the orthosteric binding site of these receptors. Herein, we report the development of the first photoswitchable allosteric modulators of Class A GPCRs, designed to target the M-1 muscarinic acetylcholine receptor. The presented benzyl quinolone carboxylic acid (BQCA) derivatives, Photo-BQCisA and Photo-BQCtrAns, exhibit complementary photopharmacological behavior and allow reversible control of the receptor using light as an external stimulus. This makes them valuable tools to further investigate M-1 receptor signaling and a proof of concept for photoswitchable allosteric modulators at Class A receptors.
Gamma aminobutyric acid type A receptors (GABA(A)Rs) play a key role in the mammalian central nervous system (CNS) as drivers of neuroinhibitory circuits, which are commonly targeted for therapeutic purposes with potentiator drugs. However, due to their widespread expression and strong inhibitory action, systemic pharmaceutical potentiation of GABA(A)Rs inevitably causes adverse effects regardless of the drug selectivity. Therefore, therapeutic guidelines must often limit or exclude clinically available GABA(A)R potentiators, despite their high efficacy, good biodistribution, and favorable molecular properties. One solution to this problem is to use drugs with light-dependent activity (photopharmacology) in combination with on-demand, localized illumination. However, a suitable light-activated potentiator of GABA(A)Rs has been elusive so far for use in wildtype mammals. We have met this need by developing azocarnil, a diffusible GABAergic agonist-potentiator based on the anxiolytic drug abecarnil that is inactive in the dark and activated by visible violet light. Azocarnil can be rapidly deactivated with green light and by thermal relaxation in the dark. We demonstrate that it selectively inhibits neuronal currents in hippocampal neurons in vitro and in the dorsal horns of the spinal cord of mice, decreasing the mechanical sensitivity as a function of illumination without displaying systemic adverse effects. Azocarnil expands the in vivo photopharmacological toolkit with a novel chemical scaffold and achieves a milestone toward future phototherapeutic applications to safely treat muscle spasms, pain, anxiety, sleep disorders, and epilepsy.
A problem of systemic pharmacotherapy is off-target activity, which causes adverse effects. Outstanding examples include neuroinhibitory medications like antiseizure drugs, which are used against epilepsy and neuropathic pain but cause systemic side effects. There is a need of drugs that inhibit nerve signals locally and on-demand without affecting other regions of the body. Photopharmacology aims to address this problem with light-activated drugs and localized illumination in the target organ. Here, we have developed photoswitchable derivatives of the widely prescribed antiseizure drug carbamazepine. For that purpose, we expanded our method of ortho azologization of tricyclic drugs to meta/para and to N-bridged diazocine. Our results validate the concept of ortho cryptoazologs (uniquely exemplified by Carbazopine-1) and bring to light Carbadiazocine (8), which can be photoswitched between 400-590 nm light (using violet LEDs and halogen lamps) and shows good drug-likeness and predicted safety. Both compounds display photoswitchable activity in vitro and in translucent zebrafish larvae. Carbadiazocine (8) also offers in vivo analgesic efficacy (mechanical and thermal stimuli) in a rat model of neuropathic pain and a simple and compelling treatment demonstration with non-invasive illumination.
Les cookies són importants per a tu, influeixen en la teva experiència de navegació, ens ajuden a protegir la teva privacitat i permeten realitzar les sol·licituds que ens facis a través del web. Utilitzem cookies pròpies i de tercers per analitzar els nostres serveis i mostrar-te publicitat relacionada amb les teves preferències, basada en un perfil elaborat a partir dels teus hàbits de navegació. Pots «Acceptar» o «Rebutjar» aquelles cookies que no siguin tècniques, així com configurar les teves preferències prement «Configurar cookies». Per a més informació, consulta la nostra Política de Cookies.
Funcionals
Sempre actiu
l’emmagatzematge o l’accés tècnic és estrictament necessari per a la finalitat legítima de permetre l’ús d’un servei específic sol·licitat explícitament pel subscriptor o l’usuari, o amb l’únic objectiu de dur a terme la transmissió d’una comunicació a través d’una xarxa de comunicacions electròniques.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.L’emmagatzematge o l’accés tècnic que s’utilitza exclusivament amb finalitats estadístiques anònimes. Sense una ordre judicial, el compliment voluntari per part del seu proveïdor de serveis d’Internet, o registres addicionals d’un tercer, la informació emmagatzemada o recuperada amb aquesta única finalitat no es pot utilitzar normalment per identificar-lo.
Marketing
L’emmagatzematge o l’accés tècnic és necessari per crear perfils d’usuari amb la finalitat d’enviar publicitat, o per fer el seguiment de l’usuari en un lloc web o en diversos llocs web amb finalitats de màrqueting similars.